Open an account

60 Degrees Pharmaceuticals

SXTP · NASDAQ

$0.9222+$0.0949 (+11.47%)TodayMarket closed ·
Prev close $0.8273

About SXTP

60 Degrees Pharmaceuticals, Inc. develops medicines for the treatment and prevention of infectious diseases. The company is headquartered in Washington, Washington Dc and currently employs 3 full-time employees. The company went IPO on 2023-07-12. The firm specializes in developing and marketing new medicines for the treatment and prevention of infectious diseases. The company is focused on using biological science and applied research to develop and commercialize new therapies for the prevention and treatment of infectious diseases. The firm's pipeline under development covers development programs for vector-borne, fungal, and viral disease utilizing three of the Company’s products: new products that contain the ARAKODA regimen of Tafenoquine; new products that contain Tafenoquine, and Celgosivir. Its lead product, ARAKODA is used for malaria prevention in individuals 18 years and older. The company is also conducting due diligence activities in relation to potential in-licensing of a product relevant to Lyme disease and an antimalarial combination partner for Tafenoquine for P. vivax malaria.

Employees
3
Headquarters
WASHINGTON, Washington Dc
Listed
Jul 12, 2023
Sector
Health Care
Industry
Pharmaceuticals
Website
60degreespharma.com

SXTP key statistics

Market cap
3.24M
Price-earnings ratio
0.00
Dividend yield
—
Average volume
220.49K
Volume
34.28K
Open price
$0.8115
High today
$0.9999
Low today
$0.8115
52 Week high
$8.62
52 Week low
$0.82

60 Degrees Pharmaceuticals (SXTP) at a glance

60 Degrees Pharmaceuticals (SXTP) last traded at $0.9222, with a market cap of 3.24M and a price-to-earnings ratio of 0.00.

Today the stock has traded between $0.8115 and $0.9999. The current price is 13.6% above the day's low and 7.8% below its high.

Volume so far is 34.28K shares, below the average of 220.49K shares a day.

Over the past year 60 Degrees Pharmaceuticals has ranged from $0.82 to $8.62, and now sits 1% of the way up that range.

60 Degrees Pharmaceuticals met or beat analyst EPS estimates in 1 of the last 8 quarters. In Q2 FY26 it reported -$0.90 per share against an estimate of -$0.6936.

The average analyst price target is $3.77, 309.2% above the current price, from 2 recent ratings.

Analyst ratings

Latest rating from each analyst over the past 12 months

50%of 2 analyst ratings say Buy
  • Buy50.0%
  • Hold50.0%
  • Sell0.0%
Price target · 3 analystsAvg $3.77
Low
$3.74
Now
$0.9222
High
$3.88

SXTP earnings

Earnings per share, reported against the analyst estimate

Beat the estimate in 1 of the last 8 quarters, by 46.5% on average.

  1. Q3 FY24: reported -$18.60 per share against an estimate of -$14.38
  2. Q4 FY24: reported -$56.80 per share against an estimate of -$16.36
  3. Q1 FY25: reported -$6.24 per share against an estimate of -$5.37
  4. Q2 FY25: reported -$5.00 per share against an estimate of -$3.92
  5. Q3 FY25: reported -$2.64 per share against an estimate of -$4.94
  6. Q4 FY25: reported -$2.34 per share against an estimate of -$2.33
  7. Q1 FY26: reported -$1.28 per share against an estimate of -$0.7752
  8. Q2 FY26: reported -$0.90 per share against an estimate of -$0.6936

SXTP news

  • Mohd Haider

    60 Degrees Pharmaceuticals Stock Falls 6% in Pre-Market Ahead of Tafenoquine Trial Interim Results: What Investors Are Watching Tuesday?

  • 12 Health Care Stocks Moving In Friday's After-Market Session

  • 12 Health Care Stocks Moving In Tuesday's After-Market Session

  • 12 Health Care Stocks Moving In Thursday's Intraday Session

  • Avi Kapoor

    Dow Gains Over 100 Points; Steel Dynamics Posts Downbeat Earnings

  • Avi Kapoor

    Crude Oil Down 2%; Abbott Shares Fall Following Q4 Results

  • Avi Kapoor

    Dow Jumps 300 Points; Procter & Gamble Shares Gain After Q2 Results

  • Press releaseGlobe Newswire

    60 Degrees Pharmaceuticals to Present at H.C. Wainwright 27th Annual Global Investment Conference

Similar companies

Companies in the same industry as 60 Degrees Pharmaceuticals

Most active stocks

Highest trading volume today

Newly listed

Companies that went public in the past six weeks

Information on this page is provided for informational purposes only and is not a recommendation to buy, sell or hold any security. Investing involves risk, including possible loss of principal. Market data is delayed at least 15 minutes and is provided without warranty. Analyst ratings, price targets and company data come from third-party sources. Past performance does not guarantee future results.